$MNK News

Last published 3w ago

3w agoMNKKeenova Presents New TERLIVAZ® (terlipressin) Data Analyses at Kidney Week 2026PR NewswireDUBLIN, Oct. 21, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that two presentations on hepatorenal syndrome-acute kidney injury (HRS-AKI) and TERLIVAZ® (terlipressin) will be shared at the American
1mo agoMNKKeenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual MeetingPR NewswireDUBLIN, Oct. 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ® (terlipressin) will be shared at the American
1mo agoMNKKeenova Announces New Presentations at the Sexual Medicine Society of North America Annual MeetingPR NewswireDUBLIN, Oct. 8, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that it will share data and insights related to men's health during three speaker presentations at the Sexual Medicine Society of North
3mo agoMNKKeenova Reports Second Quarter 2026 Financial ResultsPR NewswireStrong Performance Driven by Growth in Acthar® Gel1 and XIAFLEX®2XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study
3y agoMNKBuxton Helmsley Issues Statement on Mallinckrodt plc. Bankruptcy Filing and Disclosures Revealing Apparently Concealed Intangible Asset Depreciation ExpensesBusiness WireThe Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), the New York City-based investment advisor to certain clients with financial interests in Mallinckrodt Plc. ("Mallinckrodt" or
3y agoMNKMallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid ObligationsPR NewswireInitiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customers and Deliver
3y agoMNKMallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring PlanPR NewswireAgreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust Financial Restructuring Plan to Significantly Reduce Debt, Increase Free Cash Flow Generation, Extend
3y agoMNKBuxton Helmsley Issues Letter to Mallinckrodt Plc. Directors Regarding Bankruptcy Negotiations and Financial Disclosure ViolationsBusiness WireThe Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. ("Mallinckrodt" or the
3y agoMNKMallinckrodt plc Reports Second Quarter 2023 Financial Results and Reaffirms Full Year GuidancePR NewswireReports Second Quarter Net Sales of $475.0 Million, Reflecting a 1.3% Growth on a Reported and Constant Currency Basis Compared to the Prior Year Quarter Reports Net Loss of $747.8 Million; Adjusted EBITDA of $144.0
3y agoMNKMALLINCKRODT SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Mallinckrodt To Contact Him Directly To Discuss Their OptionsPR NewswireNEW YORK, July 29, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mallinckrodt plc ("Mallinckrodt" or the "Company")
3y agoMNKMallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) Congress 2023PR Newswire– Two scientific poster presentations at EASL 2023 will detail findings of Mallinckrodt's latest research providing insight into the therapeutic effect of TERLIVAZ® from baseline, and the clinical management of
3y agoMNKMallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023PR Newswire– Findings from two clinical studies in adults with HRS involving rapid reduction in kidney function1 provide insight into the use of terlipressin among patients with comorbidities and varying baseline characteristics2,3
3y agoMNKInhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy - NCT05871606ClinicalTrials.govMaximum safe dose of iNO for AIS patients - assessing for reperfusion hemorrhage/symptomatic intracranial hemorrhage (sICH), Change in pre-endovascular mechanical thrombectomy (IAMT) and post-IAMT core infarct volume
3y agoMNKBuxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding Continued Evidentially False Statements of FinancialsBusiness WireThe Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. ("Mallinckrodt" or the
3y agoMNKMallinckrodt plc (MNK) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoMNKMallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year GuidancePR NewswireAdvanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million;
3y agoMNKMallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023PR Newswire– Findings from two clinical study presentations in adults with HRS involving rapid reduction in kidney function1 provide insight into the appropriate use of terlipressin for the care of critically ill
3y agoMNKMallinckrodt Recognized as Industry Innovator at National Organization for Rare Disorders (NORD) 2023 Rare Impact AwardsPR Newswire– TERLIVAZ® (terlipressin) is the only FDA approved treatment for adults with HRS with rapid reduction in kidney function1 – DUBLIN, May 5, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty
3y agoMNKBuxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding Failure to Address Evidential Multibillion-Dollar Asset Value Depreciation Expense Concealment SchemeBusiness WireThe Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. ("Mallinckrodt" or the
3y agoMNKMallinckrodt to Report Earnings Results for First Quarter 2023PR NewswireDUBLIN, April 24, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023,
3y agoMNKMallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the National Kidney Foundation (NKF) 2023 Spring Clinical Meeting (SCM)PR Newswire– Two scientific abstracts spanning clinical and health economic outcomes research will be presented at the 2023 NKF SCM, showcasing the breadth of Mallinckrodt's commitment to HRS patients with rapid reduction in
3y agoMNKMallinckrodt to Present New Retrospective Data on Effect of Acthar® Gel (Repository Corticotropin Injection) to Reduce Corticosteroid Use and Burden for Advanced Sarcoidosis at the Academy of Managed Care Pharmacy (AMCP) 2023 Annual MeetingPR Newswire– Findings from a retrospective analysis suggest that treatment with Acthar Gel is associated with significant reductions in corticosteroid use compared to other fourth-line alternatives for patients with advanced
3y agoMNKBuxton Helmsley Issues Letter to U.S. Senators Warren and Whitehouse Related to Mallinckrodt Plc. $2B Concealment of Asset Value Depreciation ExpensesBusiness WireThe Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. ("Mallinckrodt" or the
3y agoMNKBuxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding $2B Concealment of Asset Value Depreciation Expenses, Releases Full Analysis to SEC and U.S. Senate Finance CommitteeBusiness WireThe Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. ("Mallinckrodt" or the
3y agoMNK MNKPFMallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 GuidancePR NewswireMade Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executing Clinical Programs and Advancing Product Development
3y agoMNK MNKPFMallinckrodt to Present at Cowen's 43rd Annual Health Care ConferencePR NewswireDUBLIN, Feb. 16, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson, President and Chief Executive Officer, will present at Cowen's 43rd
3y agoMNKMallinckrodt to Report Earnings Results for Fourth Quarter 2022PR NewswireDUBLIN, Feb. 8, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 earnings results for the period ended December 30,
3y agoMNKMallinckrodt Presents New TERLIVAZ® (terlipressin) for Injection Data on Hepatorenal Syndrome (HRS) Reversal at the Society of Critical Care Medicine (SCCM) 2023 Critical Care CongressPR Newswire– Findings from a retrospective analysis suggest that patients with baseline acute-on-chronic liver failure (ACLF) grade ≤2 treated with TERLIVAZ® plus albumin had a higher incidence of HRS reversal than those
3y agoMNKMallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific OfficerPR NewswireDUBLIN, Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM,
4y agoMNK MNKPFMallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms GuidancePR NewswireLaunched Terlivaz® Following U.S. Food and Drug Administration (FDA) Approval in September; Submitted U.S. FDA Premarket Notification Application for Next-Generation Delivery System of INOmax® Strengthened
4y agoMNK MNKPFMallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver MeetingPR Newswire– Seven scientific abstracts spanning clinical and health economic outcomes research will be presented at the AASLD Liver Meeting, showcasing the breadth of Mallinckrodt's commitment to HRS patients with rapid
4y agoMNKMallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific MeetingPR Newswire– Three scientific abstracts highlighting clinical research of terlipressin treatment for adults with HRS involving rapid reduction in kidney function1 will be presented at the ASN Scientific Meeting, reinforcing
4y agoMNKA Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients - NCT05546047ClinicalTrials.govThe change in UP/CR ratio with treatment of Acthar gel 80 units subcutaneous 2 times a week alone, The change in UP/CR ratio with treatment of Acthar gel 80 units subcutaneous 2 times a week in combination with oral Tacrolimus, The relative change in protein/creatinine ratio at 24 months, (and 3 more...)
4y agoMNKApproval of Terlivaz, Nda #022231 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 09/14/2022; Drug Name: Terlivaz, Nda #022231; Active Ingredients: TERLIPRESSIN; Company: Mallinckrodt; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 022231
4y agoMNKStrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects - NCT05517902ClinicalTrials.govPercentage of Participants Achieving Confirmed Complete Closure of StrataGraft Treatment Sites without Autograft within 12 Weeks of StrataGraft Application, Number of Participants With Treatment-emergent Adverse Events (TEAEs), Mean Percent Area of StrataGraft Treatment Site Closed at Week 12 Without Autograft Placement, Mean Percent Area of StrataGraft Treatment Site Autografted by Week 12
5y agoMNKEffect of iNO in Patients With Submassive and Massive PE - NCT04996667ClinicalTrials.govright atrial pressure (RAP), right ventricular pressure (RVP), pulmonary arterial pressure (PAP), (and 12 more...)
5y agoMNKAdrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease - NCT04958642ClinicalTrials.govNumber of participants experiencing a treatment-emergent adverse event during Part C
5y agoMNKFDA Approves StrataGraft for the Treatment of Adults with Thermal BurnsFDA Press ReleasesToday, the U.S. Food and Drug Administration approved StrataGraft for the treatment of adult patients with thermal burns containing intact dermal elements (remaining deep skin layers) for which surgical intervention is clinically indicated (also referred to as deep partial thickness burns). Thermal burns are typically caused by direct contact with an external heat source such as steam, scalding wa ...
5y agoMNKImpact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation. - NCT04870437ClinicalTrials.govFrequency of TFH cells and their activation markers, Subsequent ECP response in patients with cABMR, Concentration of pro and anti-inflammatory cytokines, (and 4 more...)
5y agoMNKStrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns - NCT04765202ClinicalTrials.govNumber of treatment sites with complete wound closure without additional autografting at Month 2, Number of subjects with durable wound closure of the study treatment sites without additional autografting at Month 12
6y agoMNKMallinckrodt Seeks Bankruptcy to Offload Opioid LiabilitiesBloombergDrug manufacturer Mallinckrodt Plc became the third major opioid maker to seek bankruptcy protection after being swamped by claims it profited from fueling the U.S. opioid epidemic.
6y agoMNKMallinckrodt Secures Broad Consensus with Key Stakeholders on Comprehensive Chapter 11 RestructuringPR NewswireMallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that it has voluntarily initiated Chapter 11 proceedings in the U.S....
6y agoMNKMallinckrodt Bankruptcy Would Hand Control Over to BondholdersBloombergMallinckrodt Plc, the maker of opioids and other drugs, is nearing a deal to hand majority ownership to its unsecured bondholders as part of a bankruptcy filing, according to people with knowledge of the plan.
6y agoMNKMallinckrodt Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1)PR NewswireMallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a...
6y agoCNSP MNK AMRN MRK+1Global Brain Tumor Therapeutics Market Targeted to Reach $3.4 Billion by 2025PR NewswireAcross the globe, there has been an increasing prevalence on brain cancer over the past few years and the industry is expected to grow as a result....
6y agoMNKMallinckrodt's Hobart, N.Y. Site Recognized With Two Manufacturing Leadership AwardsPR NewswireMallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, today announced that its Specialty Generics business has been...
6y agoMNKMallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft® Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal BurnsPR NewswireMallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for...
6y agoENDP PCG MNKDrugmaker Mallinckrodt Weighs Bankruptcy to Manage LitigationBloombergDrugmaker Mallinckrodt Plc said it may seek Chapter 11 bankruptcy protection as it works to resolve a dispute with the government over its blockbuster drug and manage claims that it profited from the opioid addiction crisis.
6y agoMNKMallinckrodt plc Reports Earnings for the Second Quarter 2020 and Highlights Pipeline AdvancementsPR NewswireSecond quarter net sales of $166.5 million net of the retrospective one-time Acthar® Gel Medicaid liability; adjusted net sales of $700.9 million, a...
6y agoMNKMallinckrodt Announces U.S. Food and Drug Administration (FDA) Advisory Committee Voted to Recommend Terlipressin for Approval to Treat Patients with Hepatorenal Syndrome Type 1 (HRS-1)PR NewswireMallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U....